Rheumatology · Clinical trials
Giant Cell Arteritis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About giant cell arteritis — and why its trials are hard
Giant cell arteritis (GCA) is the most common primary systemic vasculitis in adults over 50, affecting large and medium arteries, particularly the cranial branches of the external carotid and the aorta. Hallmark features include new headache, scalp tenderness, jaw claudication, constitutional symptoms, and markedly elevated inflammatory markers; the feared complication is irreversible vision loss from anterior ischemic optic neuropathy. GCA frequently overlaps with polymyalgia rheumatica. High-dose glucocorticoids remain the cornerstone of urgent therapy to prevent blindness, but long-term steroid exposure drives substantial morbidity, motivating steroid-sparing agents. The IL-6 receptor antagonist tocilizumab became the first FDA-approved GCA therapy in 2017 on the strength of the GiACTA trial, and in April 2025 the oral JAK inhibitor upadacitinib was approved based on SELECT-GCA. Diagnosis relies on temporal artery biopsy, temporal or axillary artery ultrasound (halo sign), and cross-sectional vascular imaging. Prompt treatment is a medical emergency to preserve sight.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Tocilizumab (Actemra) | 2017 | Steroid-sparing maintenance of remission | GiACTA (Phase 3, NEJM 2017) | Sustained glucocorticoid-free remission at week 52 | 56% with weekly tocilizumab plus 26-week prednisone taper vs 14% with 26-week placebo taper (p<0.001) |
| Upadacitinib (Rinvoq) | 2025 | Oral JAK inhibitor, steroid-sparing maintenance | SELECT-GCA (Phase 3) | Sustained remission from week 12 through week 52 | 46.4% with upadacitinib 15 mg plus 26-week taper vs 29.0% with placebo plus 52-week taper (p=0.002) |
| Glucocorticoids (prednisone) (Multiple (generic)) | (unverified) | First-line urgent induction to prevent vision loss | Standard of care; predates modern registrational trials | Symptom and inflammatory-marker control; prevention of ischemic vision loss | Long-established standard of care; not established via a modern pivotal RCT |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in giant cell arteritis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ustekinumab — Prospective open-label study in GCA (terminated early) | Study stopped early after multiple relapses during glucocorticoid tapering; failed to sustain remission | IL-12/23 blockade appeared insufficient to maintain steroid-free remission; small uncontrolled design limited conclusions |
| Abatacept — Randomized Phase 2 (AGATA, Arthritis Rheumatol 2017) | Modest benefit in relapse-free survival but did not reach the robustness needed for regulatory approval | Small sample size and borderline effect size; not pursued to a confirmatory Phase 3 registrational program (unverified for later development status) |
Choosing the right endpoint
Primary endpoints that matter in giant cell arteritis trials
- Sustained glucocorticoid-free remission at week 52 — Primary endpoint in GiACTA; combines absence of flare with adherence to a defined prednisone taper and normalized inflammatory markers
- Time to first flare — Key secondary measure of durability of disease control after induction
- Cumulative glucocorticoid dose — Captures steroid-sparing benefit, directly linked to reduced long-term corticosteroid toxicity
- Inflammatory markers (ESR/CRP) — Objective biomarkers of vascular inflammation, though IL-6 inhibitors suppress CRP independent of disease activity
How iNGENū runs giant cell arteritis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Giant Cell Arteritis clinical trials — FAQs
Why are glucocorticoids started before biopsy confirmation?
How do tocilizumab and upadacitinib reduce steroid exposure?
Is upadacitinib the first oral targeted therapy for GCA?
Ready to discuss your giant cell arteritis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal